Trichostatin A (TSA)

Name: Trichostatin A (TSA)
Brand: Selleck Chemicals
SKU: S1045
Rating: 5 (138 reviews)

For research use only.

Catalog No.S1045

138 publications

Molecular Weight(MW): 302.4

Trichostatin A (TSA) is an HDAC inhibitor with IC50 of ~1.8 nM in cell-free assays.

Selleck's Trichostatin A (TSA) has been cited by 138 publications

Cell, 2019, 178(5):1115-1131

PubMed: 31442404 ( click the link to review the publication )

Cell Metab, 2019, 29(4):886-900

PubMed: 30661930 ( click the link to review the publication )

Nature, 2017, 551(7679):247-250

PubMed: 29088702 ( click the link to review the publication )

Cell, 2017, 171(4):824-835.e18

PubMed: 29056338 ( click the link to review the publication )

Nat Biotechnol, 2015, 10.1038/nbt.3130

PubMed: 25751058 ( click the link to review the publication )

Cancer Cell, 2014, 26(4):534-48

PubMed: 25314079 ( click the link to review the publication )

Autophagy, 2020, 10.1080/15548627.2019.1709762

PubMed: 31986961 ( click the link to review the publication )

Autophagy, 2020, 15:1-13

PubMed: 32264736 ( click the link to review the publication )

Theranostics, 2020, 10(15):6790-6805

PubMed: 32550904 ( click the link to review the publication )

Free Radic Biol Med, 2020, 10.1016/j.freeradbiomed.2020.01.016

PubMed: 31972340 ( click the link to review the publication )

Signal Transduct Target Ther, 2020, 13;5(1):53

PubMed: 32398667 ( click the link to review the publication )

Cells, 2020, 21;9(5):E1280

PubMed: 32455774 ( click the link to review the publication )

Front Immunol, 2020, 3;11:36

PubMed: 32117228 ( click the link to review the publication )

Mol Neurobiol, 2020, 10.1007/s12035-019-01812-5

PubMed: 31919777 ( click the link to review the publication )

Am J Cancer Res, 2020, 10(2):523-535

PubMed: 32195024 ( click the link to review the publication )

Oncogenesis, 2020, 13;9(5):48

PubMed: 32404892 ( click the link to review the publication )

Mol Cancer Res, 2020, 10.1158/1541-7786.MCR-19-0669

PubMed: 32238439 ( click the link to review the publication )

Immunol Cell Biol, 2020, 98(4):318-331

PubMed: 31950542 ( click the link to review the publication )

Front Chem, 2020, 23;8:184

PubMed: 32266211 ( click the link to review the publication )

BMC Microbiol, 2020, 20(1):28

PubMed: 32028887 ( click the link to review the publication )

Arch Insect Biochem Physiol, 2020, 103(4):e21649

PubMed: 31777104 ( click the link to review the publication )

Cell Rep, 2020, 30(7):2195-2208

PubMed: 32075759 ( click the link to review the publication )

Theranostics, 2020, 10(5):2188-2200

PubMed: 32104503 ( click the link to review the publication )

Mol Cell, 2019, 73(4):788-802

PubMed: 30704899 ( click the link to review the publication )
Mol Cell, 2019, 74(6):1250-1263

PubMed: 31054974 ( click the link to review the publication )

Nat Commun, 2019, 10(1):5792

PubMed: 31857589 ( click the link to review the publication )

Nat Commun, 2019, 10(1):4353

PubMed: 31554795 ( click the link to review the publication )

Nat Commun, 2019, 10(1):5800

PubMed: 31863007 ( click the link to review the publication )

Nucleic Acids Res, 2019, 19;47(16):8502-8520

PubMed: 31616951 ( click the link to review the publication )

Autophagy, 2019, 1-13

PubMed: 30957628 ( click the link to review the publication )

Autophagy, 2019, 10.1080/15548627.2019.1707488

PubMed: 31878840 ( click the link to review the publication )

Cancer Res, 2019, 10.1158/0008-5472.CAN-18-2486

PubMed: 31253668 ( click the link to review the publication )

Cell Death Differ, 2019, 26(5):843-859

PubMed: 29988076 ( click the link to review the publication )

Int J Cancer, 2019, 10.1002/ijc.32425

PubMed: 31111958 ( click the link to review the publication )

Mol Ther, 2019, 27(5):1039-1050

PubMed: 30852137 ( click the link to review the publication )

EBioMedicine, 2019, 43:238-252

PubMed: 31047858 ( click the link to review the publication )

J Bone Miner Res, 2019, 10.1002/jbmr.3716

PubMed: 31112333 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):428

PubMed: 31665064 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):84

PubMed: 30777099 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):463

PubMed: 31718704 ( click the link to review the publication )

J Mol Cell Biol, 2019, 10.1093/jmcb/mjz093

PubMed: 31560394 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(5):900-908

PubMed: 30824609 ( click the link to review the publication )

Mol Neurobiol, 2019, 10.1007/s12035-019-1565-7

PubMed: 30963442 ( click the link to review the publication )

J Mol Med (Berl), 2019, 97(4):541-552

PubMed: 30806715 ( click the link to review the publication )

Pharmacol Res, 2019, 146:104281

PubMed: 31125601 ( click the link to review the publication )

Cancer Sci, 2019, 110(11):3442-3452

PubMed: 31432592 ( click the link to review the publication )

J Neurochem, 2019, 10.1111/jnc.14935

PubMed: 31811660 ( click the link to review the publication )

Front Cell Neurosci, 2019, 13:468

PubMed: 31708743 ( click the link to review the publication )
Sci Rep, 2019, 9(1):4360

PubMed: 30867438 ( click the link to review the publication )

PLoS Comput Biol, 2019, 15(2):e1006826

PubMed: 30785874 ( click the link to review the publication )

Front Genet, 2019, 10:422

PubMed: 31130994 ( click the link to review the publication )

Life Sci, 2019, 223:1-8

PubMed: 30862568 ( click the link to review the publication )

J Cell Biochem, 2019, 10.1002/jcb.29470

PubMed: 31692090 ( click the link to review the publication )

Cell Adh Migr, 2019, 13(1):285-292

PubMed: 31271097 ( click the link to review the publication )

Alcohol Clin Exp Res, 2019, 43(5):822-832

PubMed: 30860602 ( click the link to review the publication )

Oncol Rep, 2019, 41(6):3209-3218

PubMed: 31002353 ( click the link to review the publication )

Int J Mol Med, 2019, 44(5):1789-1800

PubMed: 31545402 ( click the link to review the publication )

Int J Mol Med, 2019, 43(1):285-293

PubMed: 30387821 ( click the link to review the publication )

Tuberculosis (Edinb), 2019, 118:101861

PubMed: 31526947 ( click the link to review the publication )

Reprod Fertil Dev, 2019, 31(3):473-481

PubMed: 30301509 ( click the link to review the publication )

Res Vet Sci, 2019, 126:207-212

PubMed: 31610471 ( click the link to review the publication )

Exp Ther Med, 2019, 17(6):4547-4553

PubMed: 31186678 ( click the link to review the publication )

Sci Adv, 2019, 5(3):eaav1118

PubMed: 30944854 ( click the link to review the publication )

Nat Biomed Eng, 2018, 2(8):578-588

PubMed: 31015631 ( click the link to review the publication )

J Clin Invest, 2018, 128(9):4098-4114

PubMed: 30124467 ( click the link to review the publication )

Cell Rep, 2018, 24(7):1722-1729

PubMed: 30110629 ( click the link to review the publication )

Mol Ther, 2018, 26(7):1828-1839

PubMed: 29730197 ( click the link to review the publication )

Cancer Lett, 2018, 432:121-131

PubMed: 29890207 ( click the link to review the publication )

Mol Oncol, 2018, 12(5):724-755

PubMed: 29577611 ( click the link to review the publication )

Oncogenesis, 2018, 7(11):91

PubMed: 30467308 ( click the link to review the publication )

J Proteome Res, 2018, 17(4):1436-1451

PubMed: 29564889 ( click the link to review the publication )

Plant Cell Rep, 2018, 37(1):115-123

PubMed: 28939922 ( click the link to review the publication )
Exp Cell Res, 2018, 371(1):231-237

PubMed: 30107147 ( click the link to review the publication )

Int Immunopharmacol, 2018, 65:303-311

PubMed: 30342347 ( click the link to review the publication )

Oncol Rep, 2018, 39(4):1892-1900

PubMed: 29393444 ( click the link to review the publication )

Biochem Biophys Res Commun, 2018, 503(2):420-427

PubMed: 29649477 ( click the link to review the publication )

Cell Biochem Funct, 2018, 36(8):398-407

PubMed: 30484863 ( click the link to review the publication )

Med Sci Monit, 2018, 24:461-472

PubMed: 29363667 ( click the link to review the publication )

Sci Rep, 2018, 8(1):13072

PubMed: 30166563 ( click the link to review the publication )

Cell Res, 2017, 27(7):898-915

PubMed: 28497810 ( click the link to review the publication )

Mol Cell, 2017, 67(4):566-578

PubMed: 28803781 ( click the link to review the publication )

Cell Mol Immunol, 2017, 14(4):371-379

PubMed: 26388239 ( click the link to review the publication )

Oncogene, 2017, 36(12):1707-1720

PubMed: 27694895 ( click the link to review the publication )

Chemistry, 2017, 23(13):3107-3116

PubMed: 27922200 ( click the link to review the publication )

Cancer Epidemiol Biomarkers Prev, 2017, 26(9):1411-1419

PubMed: 28619831 ( click the link to review the publication )

Eur J Med Chem, 2017, 127:531-553

PubMed: 28109947 ( click the link to review the publication )

J Biol Chem, 2017, 292(31):12842-12859

PubMed: 28634230 ( click the link to review the publication )

J Pharmacol Exp Ther, 2017, 363(2):211-220

PubMed: 28860353 ( click the link to review the publication )

J Diabetes Res, 2017, 2017:8208065

PubMed: 28191472 ( click the link to review the publication )

Int J Parasitol Drugs Drug Resist, 2017, 7(1):51-60

PubMed: 28110187 ( click the link to review the publication )

Connect Tissue Res, 2017, 58(1):64-75

PubMed: 27404795 ( click the link to review the publication )

Biochem Biophys Res Commun, 2017, 485(2):454-460

PubMed: 28192116 ( click the link to review the publication )

Oncotarget, 2017, 8(7):11937-11949

PubMed: 28060760 ( click the link to review the publication )

Nat Commun, 2016, 7:10690

PubMed: 26891683 ( click the link to review the publication )

Nucleic Acids Res, 2016, 45(3):1159-1176

PubMed: 28180300 ( click the link to review the publication )

Clin Cancer Res, 2016, 22(8):1978-88

PubMed: 26634271 ( click the link to review the publication )
Thorax, 2016, 633-45

PubMed: 27071418 ( click the link to review the publication )

J Med Chem, 2016, 59(4):1613-33

PubMed: 26681404 ( click the link to review the publication )

PLoS Pathog, 2016, 12(10):e1005950

PubMed: 27764245 ( click the link to review the publication )

Free Radic Biol Med, 2016, 99:167-178

PubMed: 27498117 ( click the link to review the publication )

Oxid Med Cell Longev, 2016, 2016:4085727

PubMed: 27746856 ( click the link to review the publication )

Am J Pathol, 2016, 186(10):2701-8

PubMed: 27555113 ( click the link to review the publication )

Mol Cell Biol, 2016, 36(22):2838-2854

PubMed: 27573019 ( click the link to review the publication )

Int J Oncol, 2016, 48(6):2591-607

PubMed: 27082124 ( click the link to review the publication )

BMC Cancer, 2016, 16(1):886

PubMed: 27842508 ( click the link to review the publication )

Mol Cell Biochem, 2016, 415(1-2):197-205

PubMed: 27000860 ( click the link to review the publication )

Oncotarget, 2016, 8(60):100975-100988

PubMed: 29254139 ( click the link to review the publication )

Genet Mol Res, 2016, 15(4)

PubMed: 27819724 ( click the link to review the publication )

Sci Rep, 2016, 6:21678

PubMed: 26902929 ( click the link to review the publication )

Tumour Biol, 2016, 37(6):8293-304

PubMed: 26729194 ( click the link to review the publication )

Tumour Biol, 2016, 37(8):10269-78

PubMed: 26831669 ( click the link to review the publication )

Nat Commun, 2015, 3;6:10091

PubMed: 26631872 ( click the link to review the publication )

EMBO Mol Med, 2015, 10.15252/emmm.201404396

PubMed: 25872941 ( click the link to review the publication )

Cancer Lett, 2015, 356(2 Pt B):828-36

PubMed: 25449774 ( click the link to review the publication )

Am J Transplant, 2015, 10.1111/ajt.13106

PubMed: 25708614 ( click the link to review the publication )

Cell Death Dis, 2015, 6:e1586

PubMed: 25569103 ( click the link to review the publication )

J Antimicrob Chemother, 2015, 10.1093/jac/dku549

PubMed: 25558076 ( click the link to review the publication )

Mol Nutr Food Res, 2015, 59(2):189-202

PubMed: 25303559 ( click the link to review the publication )

Mol Nutr Food Res, 2015, 59(2):189-202

PubMed: ( click the link to review the publication )

Am J Physiol Lung Cell Mol Physiol, 2015, 309(12):L1410-9

PubMed: 26498249 ( click the link to review the publication )
Chem Biol Interact, 2015, 242:227-34

PubMed: 26482938 ( click the link to review the publication )

Oncotarget, 2015, 6(18):15814-27

PubMed: 26158412 ( click the link to review the publication )

EMBO J, 2014, 34(1):115-29

PubMed: 25398909 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2014, 111(3):E364-73

PubMed: 24395801 ( click the link to review the publication )

PLoS Biol, 2014, 12(1):e1001758

PubMed: 24409098 ( click the link to review the publication )

Cancer Lett, 2014, 10.1016/j.canlet.2014.10.034

PubMed: ( click the link to review the publication )

Mol Cell Biol, 2014, 34(22):4143-64

PubMed: 25202123 ( click the link to review the publication )

Toxicol Appl Pharmacol, 2014, 274(1):7-16

PubMed: 24200994 ( click the link to review the publication )

Life Sci, 2014, 99(1-2):31-6

PubMed: 24486299 ( click the link to review the publication )

Biochem Biophys Res Commun, 2014, 445(2):320-6

PubMed: 24530917 ( click the link to review the publication )

Exp Hematol, 2014, 42(7):574-80

PubMed: 24607957 ( click the link to review the publication )

Sci Rep, 2014, 4:4663

PubMed: 24722541 ( click the link to review the publication )

Science, 2014, 344(6183):1252304

PubMed: 24727982 ( click the link to review the publication )

Neuropsychopharmacology, 2013, 38(9):1674-84

PubMed: 23474591 ( click the link to review the publication )

Plant J, 2013, 74(5):815-28

PubMed: 23464703 ( click the link to review the publication )

Cytokine, 2013, 65(2):121-5

PubMed: 24373940 ( click the link to review the publication )

Genes Brain Behav, 2013, 13(1):69-86

PubMed: 24286462 ( click the link to review the publication )

Epigenetics, 2012, 7(10):1161-72

PubMed: 22965008 ( click the link to review the publication )

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Description

Trichostatin A (TSA) is an HDAC inhibitor with IC50 of ~1.8 nM in cell-free assays.

Targets

HDAC ^[1]
(Cell-free assay)

~1.8 nM

In vitro

Trichostatin A inhibits the proliferation of eight breast carcinoma cell lines including MCF-7, T-47D, ZR-75-1, BT-474, MDA-MB-231, MDA-MB-453, CAL 51, and SK-BR-3 with mean IC50 of 124.4 nM (range, 26.4-308.1 nM), with more potency against cell lines that express ERα than the ERα-negative cell lines. Trichostatin A inhibits HDAC activity similarly in all the breast cancer cell lines with mean IC50 of 2.4 nM (range, 0.6-2.6 nM), and results in pronounced histone H4 hyperacetylation. ^[1] Unlike Trapoxin (TPX) and Chlamydocin which potently inhibit HDAC1 or HDAC4 but not HDAC6, Trichostatin A inhibits these HDACs to a similar extent with IC50 of 6 nM, 38 nM, and 8.6 nM, respectively. ^[2] Trichostatin A (100 ng/mL) treatment induces the expression of transforming growth factor β type II receptor (TβRII) in MIA PaCa-2 cells through the recruitment of p300 and PCAF into a Sp1-NF-Y HDAC complex that binds the DNA element of TβRII promoter, which is associated with a concomitant acetylation of Sp1 and an overall decrease in the amount of HDAC associated with the complex. ^[4]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
HEK 293	NEfrdG9HfW6ldHnvckBCe3OjeR?=	MWSwMlfPxE1?	NYrsbldSOjSq	NIflTIRmfGijbn;s	M1jpSYVvcGGwY3XzJGVP[UNiYXPleJlt[XSrb36gZY5lKGmwY4LlZZNmeyCHTnHDJIFjfW6mYX7j[UBqdiC2aHWgeI91[WxiY3XscEBtgXOjdHWgZY5lKGG2IITo[UBk\WyuIIP1doZi[2V?	MknNNlU4QDdyN{m=
TE13	NIDCNZJHfW6ldHnvckBCe3OjeR?=	Ml3WNE4{\|ryP	MoXrNlRp		NGDPeZh2eC2{ZXf1cIF1\XNiUlHTV2Y2SSCuZY\lcC=>	NX7ub4JQOjV3N{m2OlU>
TE13	NWe4OWhVSXCxcITvd4l{KEG\|c3H5	Mkj2NE4{\|ryP	M1rXWVI1cA>?		NHTQdHNqdmirYnn0d{B1cGViY3XscEBxem:uaX\ldoF1cW:w	NHLlcIMzPTV5OU[2OS=>
MEFs	MlqxSpVv[3Srb36gRZN{[Xl?	NVjMc5J1Pc7:TR?=	M1fMO\|E3cA>?		MlnDbY5kemWjc3XzJJRp\SCHUFXDJIF1fGGlaH3lcpQtKFSrcjDk[YxqfmW{eTDhcoQhfGinIHXm[olkcWWwY4mgc4YheGWmZYP0ZYwh\m:{bXH0bY9v	NG\qSmYzPTR6Mk[zOC=>
SW480	MlfGSpVv[3Srb36gRZN{[Xl?	NULmTVVIOC5zzszN	M4PMdVQ5cA>?	NEfqSnFFVVOR	NXe4UHFYemW4ZYLz[ZMhTU2W	NXnJ[FhQOjV2M{S5PVc>
PC3	MWLGeY5kfGmxbjDBd5NigQ>?	NILxbIwxNjIQvF2=	M2TvOFQ5cA>?	NYTZTlZHTE2VTx?=	NWWzOJZlemW4ZYLz[ZMhTU2W	M1P5WVI2PDN2OUm3
SW480	MXPGeY5kfGmxbjDBd5NigQ>?	NV70NZROOC5zzszN	M3TCcFQ5cA>?	Mmq2SG1UVw>?	M1fSO4F1fGWwdXH0[ZMhcW64YYPpc44h[W6mIH3p[5JifGmxbh?=	M{DJUFI2PDN2OUm3
PC3	M4L6V2Z2dmO2aX;uJGF{e2G7	NUPicppTOC5zzszN	NELFTYs1QGh?	M4\XbGROW09?	NIntS3FifHSnboXheIV{KGmwdnHzbY9vKGGwZDDtbYdz[XSrb36=	MlXVNlU1OzR7OUe=
SW480	MUHGeY5kfGmxbjDBd5NigQ>?	NHTIPGcxNjIQvF2=	NGm2N2o1QGh?	M3LXdGROW09?	MkjqbY5lfWOnczDpcoNz\WG\|ZTDv[kBJTEGFMTDhcoQhUESDQ{Kgc44hW2y3ZzDn[Y5meyCycn;tc5Rmeg>?	MkfGNlU1OzR7OUe=
PC3	MlzSSpVv[3Srb36gRZN{[Xl?	MkC2NE4y\|ryP	MXq0PIg>	NU\6TpNJTE2VTx?=	MkX1bY5lfWOnczDpcoNz\WG\|ZTDv[kBJTEGFMTDhcoQhUESDQ{Kgc44hW2y3ZzDn[Y5meyCycn;tc5Rmeg>?	NH7tTowzPTR\|NEm5Oy=>
A431	Mn\xRZBweHSxc3nzJGF{e2G7	NXnLclVZOi9zMD:1NE8yODCwTR?=	MX:0PIg>	MUXEUXNQ	MVvpcohq[mm2czD0bIUh[2WubDDndo94fGh?	M4P0cVI2OzdzME[5
A431	NUjFS\|NnTnWwY4Tpc44hSXO\|YYm=	NXL2flFrPTCwTR?=	NGDXPVMzNzZxMUKvNlRp	NUfDSmhwTE2VTx?=	NYD1Z5Zn[WO2aY\heIV{KHB{MTDhcoQhcW6qaXLpeJMhSVSIMzDlfJBz\XO\|aX;u	NYTWN2huOjV\|N{GwOlk>
MDA-MB-231	MkPKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXPJbJRZOC14MEDuUS=>	M3zFbVI1cA>?	MlG5SG1UVw>?	NH[0eHpKSzVyIH;mJFExOG6P	NFXqSnEzPTF7MkeyNS=>
MCF7	M3WxT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{TOZlAuPjBybl2=	NGDybo4zPGh?	NXOxTG1NTE2VTx?=	MnvGTWM2OCCxZjC3OY5O	MYmyOVE6Ojd{MR?=
SKOV-3	NV\4fItMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkDFNU0yOM7:TR?=	NF;LbYwzPGh?	MlXxSG1UVw>?	MXPJR\|UxKG:oIEWuOu69VQ>?	MX:yOVE3QTR7MR?=
A549	NGS3UHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFrtUY8yNTFyzszN	MmfvNlRp	M1nrRWROW09?	MWjJR\|UxKG:oIEOuNu69VQ>?	M1XSflI2OTZ7NEmx
SKOV-3	M2H2[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHXEb3IxNjFvMd88US=>	MVq0PIg>	MkjaSG1UVw>?	NEW5N4hKSzVyIH;mJFAvP87:TR?=	MVmyOVE3QTR7MR?=
A549	Mlj0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2LIU\|AvOS1zzszN	MmHVOFhp	M{jLemROW09?	NXTyc\|REUUN3MDDv[kAxNjJ6zszN	M3nSWVI2OTZ7NEmx
SKOV-3	M{LH[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWCwMlAyNTBwOd88US=>	NET1fWU4Omh?	M3y1cWROW09?	MVjJR\|UxKG:oIECuN\|LPxE1?	MY[yOVE3QTR7MR?=
A549	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVXGZmhHOC5yMT2wMlnPxE1?	NHywZXU4Omh?	NHq1S5NFVVOR	NEDlN5VKSzVyIH;mJFAvODcQvF2=	MoOyNlUyPjl2OUG=
HeLa	MXTGeY5kfGmxbjDBd5NigQ>?	NGHadlMzPTCwTR?=	MnTnNVZp	NYLFdYkyTE2VTx?=	NFvlO3ZqdmO{ZXHz[ZMhS1mSMVGxJI1TVkFiZYjwdoV{e2mxbtMg	NUTPOo1TOjVzMU[2PFg>
CNE2	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2jrRlExOC14MEDuUS=>	NWXpSmZPOjRxNEivO\|Jp		MXLpcohq[mm2czD0bIUheHKxbHnm[ZJifGmxbjDpckBiKHSrbXWtJIFv\CCmb4PlMYRmeGWwZHXueEBu[W6wZYK=	NXXqO\|hyOjR7Nkm5NFE>
PC3	MlfzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEfHPGIyODBvMUCwNI5O	NGTiNIozPGh?		M3zPfGlEPTBib3[gN\|Axdk1?	NXXnbHFwOjR6NUS2OVg>
LNCaP	NFTsNJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXmxNFAuOTByMH7N	NYrEPYhvOjSq		MXzJR\|UxKG:oIEOwNI5O	NVPCTIN2OjR6NUS2OVg>
HeLa	M4TubGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIXsW5Mz\|ryP	NVfOb3dRPDiq		NXTmcJVQ\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIFjd3W2IEK1KS=>	MWSyOFg1PjF\|NR?=
HMEC-1	M4W4fmZ2dmO2aX;uJGF{e2G7	NES0blM{ODCwTR?=	NYDIfmpnOjSq		NV\ZfYJKcW6lcnXhd4V{KGW6cILld5Nqd25ib3dCpHZGT0[UM9MgcXJPSQ>?	NWTPb2lkOjR5MUC2N\|E>
HeLa	MkL6SpVv[3Srb36gRZN{[Xl?	NGewZmwydU1?	MV6wMlVp		NUHLToZ4[WKxbHnzbIV{KHSqZTD0c5RidCCKRFHDJIFkfGm4aYT5	NUTtWpVUOjR5MEe0O\|Q>
ACP02	NUHrWG9ST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX[yOVAwOzVyL{WwNI5O	M1vCfFI1cA>?		M2XYOIRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDv[kBieHC{b4jpcYF1\Wy7IEewxsAmKGG2IEK1NOKhdk1?	MVKyOFY3QDV2Nx?=
ACP03	MoT0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYCyOVAwOzVyL{WwNI5O	NFyyXFAzPGh?		Mnni[IVkemWjc3XzJINmdGxidnnhZoltcXS7IH;mJIFxeHKxeHntZZRmdHliN{FCpEUh[XRiMkWwxsBvVQ>?	NHXtdXozPDZ4OEW0Oy=>
U87 GBM	NYLUSVdyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFPCO5MyODBxM{CwM\|UxOCCwTR?=	NUHlOoo2PzJiaB?=	MVixNFAmKGW2aHHuc4w>	M4G2bpJm\HWlZYOgcYVidiClZXzsJI52dWKncjDifUA{OSxiNUSsJIFv\CB3ONMgKS=>	NHP5cW0zPDR4NEi0NS=>
U87 GBM	NU[3UpVyTnWwY4Tpc44hSXO\|YYm=	M1HlS\|ExOC93MECgUo0>	NEL3R4g1QCCq	M2jUcVExOCViZYToZY5wdA>?	MUDJcoR2[2W\|IGPlcoV{[2WwY3WtUIls\SCDbITldoF1cW:wczDpckBPfWOuZXHyJG1wenCqb3zv[5k>	MojzNlQ1PjR6NEG=
RPE	M4LJ[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFXqVJAxNjJxMD60M\|AvQC9zIN88US=>	NYH3W\|lTOjRxNEivO\|IhcA>?	NFjhWVdFVVOR	NVXhNWtncW6qaXLpeJMhfGinIIDyc4xq\mW{YYTpc44h[nliY3XscEBkgWOuZTDhdpJme3R?	NVm3XVFxOjR2NU[2NFI>
HT29	M4\lUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFLvfFEyQDBibl2=	MoHHO\|IhcA>?		M2XoN2lEPTBib3[gNVgxKG6P	MYmyOFM3QDJ4NR?=
hMSCs	NHzESFVHfW6ldHnvckBCe3OjeR?=	MVe2MlI2KG6P	NXLY[JZ2OjRiaB?=	M3zC[mROW09?	NVX6T3R6e3SjYnnsbZpmeyCKaYP0c45mKEGlZYT5cIF1cW:wIHHu[EB1cGViRYjwdoV{e2mxbjDv[kBRdHW{aYDveIVvfCCJZX7ldy=>	NEm0TYozPDNzMkO1Oi=>
Huh7	MoXqSpVv[3Srb36gRZN{[Xl?	NYfvflZvOC5zL{CuOU8yNjBizszN	MkHWNlRp		Ml7wd5VxeHKnc4Pld{B[XEiGQ{Kg[4Vv\SCneIDy[ZN{cW:w	MYiyOFI3QTZ5Mh?=
SKOV3	MoHnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYn3PXp5OC5yNT2yJO69VQ>?	M37oVFExNzJ2L{S4JIg>	M{DGcmROW09?	NHjCRXhu\WSrYYTld{Boem:5dHigZZJz\XO2IHnuJIEh[2:wY3XueJJifGmxbj2gZY5lKHSrbXWt[IVx\W6mZX70JI1idm6nch?=	MV2yOFIzOzhyMR?=
A2780	NH;qVWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEPXeHAxNjB3LUKg{txO	MYCxNE8zPC92ODDo	M{K3b2ROW09?	M1fsOo1m\GmjdHXzJIdzd3e2aDDhdpJme3RiaX6gZUBkd26lZX70doF1cW:wLTDhcoQhfGmvZT3k[ZBmdmSnboSgcYFvdmW{	NF;YVlMzPDJ{M{iwNS=>
SRA01/04	NF7xZ5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mmn6NE4zKM7:TR?=	MVW0PEBp	NFHvWYZFVVOR	NUH0fZBie3WycILld5NmeyClZXzsJJBzd2yrZnXyZZRqd25idHjyc5VocCC\|dYDwdoV{e2mwZzD0bIUhWEl\|Sz;Bb5QtKHB\|OF3BVGsh[W6mIFXST\|EwOiC\|aXfuZYxqdmdicHH0bJdigXN?	M13tclI1OTV5OEe4
HLEB3	M{DKVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXiwMlIh\|ryP	MYG0PEBp	Ml7iSG1UVw>?	MWnzeZBxemW\|c3XzJINmdGxicILvcIln\XKjdHnvckB1cHKxdXfoJJN2eHC{ZYPzbY5oKHSqZTDQTVNMN0GtdDygdFM5VUGSSzDhcoQhTVKNMT:yJJNq\26jbHnu[{Bx[XSqd3H5dy=>	MkfsNlQyPTd6N{i=
SRA01/04	NHLM[pVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4PEdVAvPC9yLkig{txO	NHzLVWk1QCCq	NX7mbYR[TE2VTx?=	NWrzWmM6cW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?=	NHfqeJgzPDF3N{i3PC=>
HLEB3	M1nUTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnXONE41NzBwODFOwG0>	MnL1OFghcA>?	NVXTSlVLTE2VTx?=	NGXkc\|ZqdmS3Y3XzJINmdGxiYYDvdJRwe2m\|	M13TS\|I1OTV5OEe4
HCT116	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV:wMlIh\|ryP	MX6xNkBp		MYPlcohidmOnczDj[YxtKGGyb4D0c5NqeyCrbnT1Z4VlKGK7IILh[IlifGmxbh?=	MYWyOFEzOjJ\|MR?=
CA46	NITveVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXHVPIFZOy94L{GyM\|I1NzR6IH7N	MnPOOFghcA>?		M1\uTIlvcGmkaYTzJJRp\SClZXzsJJBzd2yrZnXyZZRqd25iYYSgNlQh[W6mIES4JI5OyqB?	MnHmNlQxPjR7NUG=
PMNs	MoSwSpVv[3Srb36gRZN{[Xl?	MYqzNEBvVQ>?	Mkf5OFghcA>?		NXLDXXNZcW6qaXLpeJMh\W[oZYLvZ5l1d3OrczygTGRCSyCjY4Tpeol1gSCjbnSgVoFkKGGldHn2bZR6	M1zkV\|I{QTh6NkG3
H1299	Mlr1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUSxxsDPxE4EoB?=	NX[xcXAzOjRxNEivO\|IhcA>?	NHu1WlZmfGijbn;s	NFLDRpRqdmO{ZXHz[ZMh[2WubDDk[YF1cCCjZoTldkAzPGh?	NYXSOo9{OjN7MU[2NFk>
A549	MnTZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnPZNE4zPS9yLkWvNUDPxE1?	NYXWUIxTOjRxNEivO\|IhcA>?	M{jM[YV1cGGwb3y=	MlLubY5pcWKrdIOgeIhmKGOnbHyg[5Jwf3SqIHnuJINwdmOnboTyZZRqd25iYX7kJJRqdWVvZHXw[Y5l\W62IH3hco5meg>?	MWqyN\|g3Pzl7MR?=
H1299	M3fkbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYS5R2oxOC5{NT:wMlUwOSEQvF2=	MYOyOE81QC95MjDo	NFzWVmdmfGijbn;s	M1nEe4lvcGmkaYTzJJRp\SClZXzsJIdzd3e2aDDpckBkd26lZX70doF1cW:wIHHu[EB1cW2nLXTldIVv\GWwdDDtZY5v\XJ?	M3TnSlI{QDZ5OUmx
A549	M{\2SWFxd3C2b4Ppd{BCe3OjeR?=	MmLnNE42NzFizszN	MVO0PEBp	Mn3V[ZRp[W6xbB?=	NEWzcY1qdmS3Y3XzJINmdGxiYYDvdJRwe2m\|	MYqyN\|g3Pzl7MR?=
H1299	MWDBdI9xfG:\|aYOgRZN{[Xl?	Mnq2NE42NzFizszN	M1znbVQ5KGh?	M1H4OYV1cGGwb3y=	NXuySXp6cW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?=	MYeyN\|g3Pzl7MR?=
SUM149PT	Ml33S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV;OfZZ6Oi95LkWvNVAh\|ryP	NYDBTYpoPDhiaB?=	NGT3SmlFVVOR	MUfpcoR2[2W\|IHPlcIwh\GWjdHigZZQhOiEQvF2gbY5{\W6\|aYTpeoVtgQ>?	NEG4WnozOzd7Mk[zPC=>
SUM190PT	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoK0OVAwOTByL{K1NEBvVQ>?	Ml\zOFghcA>?	MWfEUXNQ	NFHZZVRqdmS3Y3XzJINmdGxiZHXheIgh[XRiNUCgcm0he2Wwc3n0bZZmdHl?	NEWwbG4zOzd7Mk[zPC=>
HCT1	NFLsbFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXnkXVdsOC5{L{GuNE82NjBizszN	MljHNVIwOjRxM{[vOFghcA>?		NETVe41qdmS3Y3XzJINmdGxiZHXheIghcW5iY3;uZ4VvfHKjdHnvck0h[W6mIITpcYUu\GWyZX7k[Y51KG2jbn7ldi=>	MYCyN\|c4ODByMB?=
Lovo	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUOwMlIwOS5yL{WuNEDPxE1?	NVPJPVRiOTJxMkSvN\|YwPDhiaB?=		MXPpcoR2[2W\|IHPlcIwh\GWjdHigbY4h[2:wY3XueJJifGmxbj2gZY5lKHSrbXWt[IVx\W6mZX70JI1idm6nch?=	Ml\NNlM4PzByMEC=
AGS	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkfnNE4xOTVvMTFOwG0>	NXPYWo9xPzJiaB?=		MXnpcoR2[2W\|IHPlcIwh\GWjdHigZ49v[2WwdILheIlwdiCmZYDlcoRmdnSueR?=	MXyyN\|c1PTB{NB?=
Huh7	NVf6OYE2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M33FOlEh\|ryP	NYfUV5c6OjRiaB?=	MWHEUXNQ	NEDuTG1z\WS3Y3XzJIFjd3W2IEKwKUB3cWGkaXzpeJnDqA>?	MXmyN\|Y1Ozl\|Mx?=
ECC1	NG\NfmdHfW6ldHnvckBCe3OjeR?=	MYi1NFAhdk1?	MmHoOUBl	MVrEUXNQ	NFu0Z2RqdmS3Y3XzJGwyS0GPwrDlfJBz\XO\|aX;uJINwNXS{ZXH0cYVvfCC5aYToJFUuSXqjQx?=	M{nQSlI{PTNyN{[5
HEC1A	NX62NIZ1TnWwY4Tpc44hSXO\|YYm=	MWm1NFAhdk1?	NHjhPGY2KGR?	NUHqUGlQTE2VTx?=	NIXa[4pqdmS3Y3XzJGwyS0GPwrDlfJBz\XO\|aX;uJINwNXS{ZXH0cYVvfCC5aYToJFUuSXqjQx?=	NVnIbZQ2OjN3M{C3Olk>
EN1	NF3leVVHfW6ldHnvckBCe3OjeR?=	NXfxN2JvPTByIH7N	M4HlflUh\A>?	MXnEUXNQ	MnLybY5lfWOnczDMNWNCVcLiZYjwdoV{e2mxbjDjc{11emWjdH3lcpQhf2m2aDC1MWF7[UN?	NHv0ZoEzOzV\|MEe2PS=>
MFE296	MUHGeY5kfGmxbjDBd5NigQ>?	NV;6SlB4PTByIH7N	MoW5OUBl	Mn3MSG1UVw>?	M4DjbIlv\HWlZYOgUFFESU4EoHX4dJJme3Orb36gZ48ufHKnYYTt[Y51KHerdHigOU1CgmGF	NFv5fGYzOzV\|MEe2PS=>
HASMCs	MWXGeY5kfGmxbjDBd5NigQ>?	NFjGd4MxNTVyMDDuUS=>	MkDQOkBl		Mofw[I94di2{ZXf1cIF1\XNidHjlJIV5eHKnc4Ppc44hd2ZiSFHER{BidmRiY3XscEB3cWGkaXzpeJk>	NUXudpJ4OjN3MUi0Olc>
U373	NULRNGZtTnWwY4Tpc44hSXO\|YYm=	MXmwMlI2NzBwNT:xJO69VQ>?	NHHOe3ozPCCq		MXzpcoNz\WG\|ZYOgVHIuSiCneIDy[ZN{cW:wIHPvMZRz\WG2bXXueEB4cXSqIEXBfoFlSw>?	MkLnNlM1PzRzN{G=
ARN8	M3flUGZ2dmO2aX;uJGF{e2G7	NI\4ZWwxNjB3LUKg{txO	MXyyOEBp		NITpN3Nz\WS3Y3XzJJRp\SCrbnT1Z5Rqd25ib3[gdFU{NWSncHXu[IVvfCCpZX7ld{BjgSCQdYTsbY4uOw>?	NY\MdIdCOjN2N{C1OFA>
MCF7	MXvGeY5kfGmxbjDBd5NigQ>?	MofGNE4xPS1{IN88US=>	MkDtNlQhcA>?		MUXy[YR2[2W\|IITo[UBqdmS3Y4Tpc44hd2ZicEWzMYRmeGWwZHXueEBo\W6nczDifUBPfXSuaX6tNy=>	NUTRfZBMOjN2N{C1OFA>
H1299	MYXGeY5kfGmxbjDBd5NigQ>?	NIC0TVgxNjN\|4pETNeKhyrWP	MoH3NlQwPDhiaB?=	MojISG1UVw>?	M1fXTolv[3KnYYPld{BGNWOjZHjldolvKHC{b4TlbY4hdGW4ZXzzJIRwe2ViZHXw[Y5l\W62bIm=	NVfoRo5VOjN2NkG5O\|U>
H1299	MoX1SpVv[3Srb36gRZN{[Xl?	MkK1NE42KM7:TR?=	NHHjOmk1QCCq	NH\4UYtFVVOR	NYe2OpdtcW6qaXLpeJMhfGinIH3p[5JifG:{eTDwc5RmdnSrYXygZ49u[mmwZTD3bZRpKHOrbHnibY5qdg>?	Mo\RNlM1PjF7N{W=
H1299	MmLCSpVv[3Srb36gRZN{[Xl?	MknyNE42KM7:TR?=	M{m1U\|Q5KGh?	NIjI[pVFVVOR	NYGxfnZmcW6qaXLpeJMhfGinIHnueoF{cX[nbnXzd:KhKGOxbXLpcoUhf2m2aDDzbYxq[mmwaX6=	MWKyN\|Q3OTl5NR?=
MG-63	NUfGR45NT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWDHPZQ3OC5\|IN88US=>	MmnxNVIuQTZiaB?=	NID1OnJFVVOR	NF30dpVqdmirYnn0d{B1cGViY3XscEBoem:5dHigZ48ufHKnYYTt[Y51KHerdHigcYV1\m:{bXnu	NV3JfolUOjN2NUG4NVc>
LM8	NIrQXXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmfJNE4{KM7:TR?=	NFHsT\|IyOi17NjDo	MVPEUXNQ	M3XsNolvcGmkaYTzJJRp\SClZXzsJIdzd3e2aDDjc{11emWjdH3lcpQhf2m2aDDt[ZRnd3KvaX6=	M4[xXlI{PDVzOEG3
K562	NFrLSFBHfW6ldHnvckBCe3OjeR?=	MXSwMlUh\|ryP	MW[yOEBp	M120T4V1cGGwb3y=	NXyyPVZX\GWlcnXhd4V{KHSqZTDlcpp6dWViYXP0bZZqfHlib3[gTGRCS3NiY3:teJJm[XSvZX70JJdqfGhiY4XyZ5VucW5?	MX:yN\|Q{ODl3Nx?=
HEL	MoL1SpVv[3Srb36gRZN{[Xl?	M3\6OlAvPSEQvF2=	NI\wXpozPCCq	M1vhboV1cGGwb3y=	M{LjdIRm[3KnYYPld{B1cGViZX76fY1mKGGldHn2bZR6KG:oIFjERWN{KGOxLYTy[YF1dWWwdDD3bZRpKGO3cnP1cYlv	MlHENlM1OzB7NUe=
HL60	MUPBdI9xfG:\|aYOgRZN{[Xl?	NXTMRWZZOSEQvF2=	MV:yOEBp		Mm\MbY5lfWOnc9MgZ4VtdCCmZXH0bC=>	NXWyeZBjOjN2MEC1NVk>
KG1	MonIRZBweHSxc3nzJGF{e2G7	NFzvbWQyKM7:TR?=	MoHNNlQhcA>?		MWnpcoR2[2W\|wrDj[YxtKGSnYYTo	M{jiRlI{PDByNUG5
Kazumi	NHfHe2dCeG:ydH;zbZMhSXO\|YYm=	MnLzNUDPxE1?	M2[3NVI1KGh?		MYrpcoR2[2W\|wrDj[YxtKGSnYYTo	Ml;uNlM1ODB3MUm=
K562	NWPBR2VnSXCxcITvd4l{KEG\|c3H5	M4rx[FEh\|ryP	MmDzNlQhcA>?		M1HjcIlv\HWlZYRCpINmdGxiZHXheIg>	M2LuV\|I{PDByNUG5
THP1	NW\XeZVPSXCxcITvd4l{KEG\|c3H5	MXOxJO69VQ>?	MUKyOEBp		MmPqbY5lfWOnc9MgZ4VtdCCmZXH0bC=>	NEnSTIEzOzRyMEWxPS=>
SH-SY5Y	NY\qfHdlTnWwY4Tpc44hSXO\|YYm=	NWL6bWZQOjVyIH7N	Mo[xNVYhcA>?		MX\jbIFv\2W\|IHX4dJJme3Orb36gdIF1fGW{bjDv[kBo\W6nczDpcpZwdH[nZDDpckBkcG:uZYP0[ZJwdCC\|eX70bIV{cXNuIIXweIFs\SCjbnSg[YZndHW6	M37UV\|I{OzJ4NEKy
HEK293	MXfGeY5kfGmxbjDBd5NigQ>?	MUKxJOK2VcLi	NFzGXIIyQCCqwrC=		NH6yWJBqdmirYnn0d{B1cGVia3HsbZJqdi15LX3l[IlifGWmIILlZ5J2cXSvZX70JI9nKHO7boDobYxqdi1zIHHn[5Jm\2G2ZYOgbY51dyCjZ3fy[ZNwdWW\|	M{P5eVI{Ojh2OES4
HTK	MWTGeY5kfGmxbjDBd5NigQ>?	M3rsSlQxOCCwTR?=	NEfEZVE4OiCq		NUHhcJBicW6qaXLpeJMhXEeILd8y5qCUUW6mdXPl[EBOgW:oaXLyc4Jt[XO2IFTp[oZmemWwdHnheIlwdg>?	MYiyN\|I5PDByMh?=
HTK	MmH2SpVv[3Srb36gRZN{[Xl?	MlrKNVAxNThyMH7N	NX\JZZV4PzJiaB?=		Ml;DZoxw[2u\|IGTHSk3PuuLCk1nu[JVk\WRiUl;TJIFv\CCKMl:yxsBC[2O3bYXsZZRqd25?	NWnXd5NJOjN{OESwNFI>
Caco-2	M4LyRmZ2dmO2aX;uJGF{e2G7	NHjMZY0yKML3TdMg	M1X2RVI1KGh?		NF\WcmZl\WO{ZXHz[ZMhW0WUVDDwdo91\WmwIHX4dJJme3Orb36=	M33CUFI{OTl3MEew
HeLa	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGHRWGIyODBibl2=	MViyOEBp	NVT4dXplTE2VTx?=	M{i5eWlEPTBib3[gNVAxdk1?	Mlv6NlMyPjV5NEi=
HeLa	NIHGfnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEjrfoE1OCCwTR?=	MkXEOFghcA>?	MXLEUXNQ	NXP5UVAzUUN3MDDv[kA1OG6P	M{LpWlI{OTZ3N{S4
HeLa	NUn4V3FCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlL6NlAhdk1?	NUXVUVFRPzJiaB?=	NF\WWm5FVVOR	NVyycpFtUUN3MDDv[kAzOG6P	M2jnc\|I{OTZ3N{S4
HeLa	M1HlT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFL2Z4oyOC9\|MD:1NEBvVQ>?	NHPUbYM4OiCq	MmLESG1UVw>?	MoXObY5kemWjc3XzJJRp\SCwdX3i[ZIhd2ZiTV3QJEjPnM7qbTmgcI9{eyClZXzsd{Bld3OnIHTldIVv\GWwdHz5	MnXhNlMyPjV5NEi=
MDA-MB-231	NILN[IRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIX2XFgzPS12MECgcm0>	NUTTUWo5PDhiaB?=		NGnHW2xKSzVyIH;mJFI3Oy5{bl5CpC=>	NUDne2ZrOjNyNUWxPVg>
MCF-7	NIfwcZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF\BfoQzPS12MECgcm0>	NHfQS201QCCq		M4XmNmlEPTBib3[gNlIxNjSwTR?=	M2fCZ\|I{ODV3MUm4
ECC-1	NVjSOIhMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFjpPIQyODBibl2=	NEG2cWEzPCCq	Mo\s[ZRp[W6xbB?=	M3vKNIlv[3KnYYPld{B1cGVicILvdI9zfGmxbjDv[kBieG:ydH;0bYMhdnWlbHXpJJRwKDN3JR?=	NUO1VndSOjNyMki4NFM>
HEC-1A	NHnpNJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX[xfVRJOTByIH7N	NECz[3ozPCCq	MWrleIhidm:u	NEnQVWRqdmO{ZXHz[ZMhfGinIIDyc5BwenSrb36gc4Yh[XCxcITveIlkKG63Y3zlbUB1dyB\|OTW=	MVqyN\|AzQDhyMx?=
NHAC-kn	NX25do5NT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVfu[3BmOTBxMUCwM\|UxOCCwTR?=	M1rnVFEzKGh?	NIDzV5NFVVOR	M1LnTmlEPTBib3[gOVAxdk1?	MXSyN\|AyPzh5MR?=
A549	NIf1SmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIfSOHEzPTBibl2=	MmPNOk04OiCq	Mn3vSG1UVw>?	MVfjZZV{\XNiYTDndoVifGW{IHnubIljcXSxcomg[YZn\WO2IHPvcYJqdmVid3n0bEBVYFRib4Kg[ZJtd3Srbnni	MVWyNlk6PDd6MB?=
MG-63	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVLPUWNKOzByIH7N	MojZNVIhcA>?	MnXySG1UVw>?	MVPpcohq[mm2czD0bIUh[2WubDDndo94fGhidH:gPFYm	MWOyNlc6QTN\|OB?=
MG-63	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NY\jcYJmOzByIH7N	NUHhVZZVOjRiaB?=	MnLjSG1UVw>?	MYrpcohq[mm2czD0bIUh[2WubDDndo94fGhidH:gOlcm	NUjOUIlxOjJ5OUmzN\|g>
MG-63	MkLYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{HHSlMxOCCwTR?=	M37PPFQ5KGh?	NYHGT4Z1TE2VTx?=	NXS2PHl1cW6qaXLpeJMhfGinIHPlcIwh\3Kxd4ToJJRwKDV4JR?=	NUjSS4VqOjJ5OUmzN\|g>
HL60	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWqxOVAuOzVyIH7N	M3q1ZlI1KGh?		M2rrUolv[3KnYYPld{Bk\WyuIHHwc5B1d3Orc9Mge4hmdiClb37j[Y51emG2aX;ud{BpcWeqZYKgeIhidiB{NUCgcm0>	NXLqWVR3OjJ5NUO3N\|k>
U937	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUX4eoFqOTVyLUO1NEBvVQ>?	M3u2UlI1KGh?		MUXpcoNz\WG\|ZYOgZ4VtdCCjcH;weI9{cXQEoIfo[Y4h[2:wY3XueJJifGmxboOgbIlocGW{IIToZY4hOjVyIH7N	M1jRN\|IzPzV\|N{O5
SCC-6	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXSyNFAuOzJyMDDuUS=>	NEi4OGsyOi9{ND:0PEBp	MmXFSG1UVw>?	M{S4NIlvcGmkaYTzJJRp\SCycn;sbYZmemG2aX;uJI9nKFOFQz22JINmdGy\|IHnuJIEh\G:\|ZT2gZY5lKHSrbXWt[IVx\W6mZX70JI1idm6nch?=	MlHENlI2PTJ\|MkG=
U87	MmjCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M36zNlExOC1\|MECgcoc>	NHX1bY4zPCCq		Mor3bY5pcWKrdIOgeIhmKGOnbHyg[5Jwf3SqIITvJFczLSBiYYSgNlAxdmd?	MVGyNlI4ODh2OR?=
K562	M4XjRWZ2dmO2aX;uJGF{e2G7	MVKxJO69VQ>?	NHv0VZQyOiCq	NXX0fmVUTE2VTx?=	NWnwVYpV\W6qYX7j[ZMhfGinIHX4dJJme3Orb36gc4YhWlWQWEOgbY5lfWOnZDDifUA2NWG8YT3D[HI>	NVPzZnBOOjJzN{mxPVg>
Reh	NW\ZNoxZTnWwY4Tpc44hSXO\|YYm=	NIe1SIsxNjNxMTFOwG0>	MVOxNkBp	MUHEUXNQ	M3XMRoVvcGGwY3XzJJRp\SCneIDy[ZN{cW:wIH;mJHJWVlh\|IHnu[JVk\WRiYomgOU1igmFvQ3TS	MoO4NlIyPzlzOUi=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	EGFR / STAT3 ; PubMed: 31289542 Oncol Lett Expression of EGFR and STAT3 in PC3 cells treated with TSA. PC3 cells were plated in 6-cm dishes, and 0.25, 0.5 or 1 µM TSA was added for 24 h. DMSO was added into the control group wells. Cells were collected and lysed with lysis buffer and the protein expression analyzed via western blotting. Cyclin D1 / CDK6 / CDK4 / p-RB / RB; PubMed: 31289542 Oncol Lett Expression of cyclin D1, CDK6, CDK4 and RB, and the phosphorylation of RB, was detected in PC3 cells treated with TSA for 24 h. MMP-1 / MMP-3 / MMP-13 / TIMP-1; PubMed: 27431944 Mol Med Rep Chondrocytes were pretreated with increasing concentrations of TSA for 2 h, followed by stimulation with 5 ng/ml IL-1β for 24 h. Acetyl-H3 (Lys27) / H3 (96C10) / Acetyl-H4(Lys8) / H4(L64C1); PubMed: 27431944 Mol Med Rep Chondrocytes were treated with increasing concentrations of TSA for 24 h. α-H3Ac / α-H4Ac / α-H3K9Ac / α-H3K9 S10 / α-H3K4 me / α-H3K4 me2 / α-H3K9 me2; PubMed: 23802098 Front Oncol Histone acetylation occurs directly at the promoter region of IL-23R. The ChIP assay demonstrates that TSA treatment results in an increase in the acetylation of histone H3 and H4. A549 cells were cultured in the presence or absence of TSA (250 ng/mL) for a period of 24 h. Subsequently, a ChIP assay was performed using the following antibodies; pan acetyl-histone H3 (H3Ac), pan acetyl-histone H4 (H4Ac), acetyl-histone H3 Lys 9 (H3K9Ac), acetyl-histone H3 Lys 9/14 (H3K9/14ac), acetyl-histone H3 Lys 9 phosphoSer10 (H3K9S10), methyl-histone H3 Lys 4 (H3K4Me), di methyl-histone H3 Lys 4 (H3K4Me2), and di methyl-histone H3 Lys 9 (H3K9Me2). Input DNA serves as a positive control as recommended by the manufacturer (Diagenode). A no antibody control was included to test for non-specific binding (UT, untreated; TSA, Trichostatin A).	31289542 27431944 23802098
Immunofluorescence	α-C/EBPβ / α-HP1α ; PubMed: 21122806 Exp Cell Res 3T3-L1 preadipocytes were grown on coverslips for three days and induced to differentiate by treatment with MDI (48 h) in the presence of vehicle (-TSA) or 87 nM Trichostatin A (+TSA). Under these experimental conditions: A-H Cells were fixed and permeabilized in cold methanol, subjected to IIF with the indicated antibodies, and nuclei were counterstained with DAPI. Scale bar, 5 μm. α-HDAC1 ; PubMed: 29045501 PLoS One MCF-7 cells were treated with indicated concentrations of trichostatin A (optical sections E-H, respectively) for 12 hours, fixed, permeabilized and optical sections were obtained by laser scanning confocal microscopy. Fluorescence signal for HDAC1 is shown in green (left panels), DAPI staining is shown in blue (middle panels), and merged optical sections are shown in the right panels. α-tubulin / acetylated histone 3; PubMed: 27957719 Neurotherapeutics Immunocytochemistry for acetylated α-tubulin (red) and acetylated histone 3 (green) on N2a cells treated with 1 μM TSA, ACY-738, and ACY-775.	21122806 29045501 27957719
Growth inhibition assay	Cell viability (A549 cells); PubMed: 27571418 PLoS One Cytotoxicity of histamine determined by MTT assay in A549 cells. Cell viability (MDA-MB-231 cells); PubMed: 27548148 Int J Mol Sci The human breast cancer cells (MDA-MB-231) were incubated with various concentrations of TSA (0–300 nM) for 24 h. Cell viability was measured by WST-8. Cell viability (PC3 cells); PubMed: 31289542 Oncol Lett PC3 cells were plated in a 96-well plate and treated with different doses of TSA (0, 0.25, 0.5 and 1 µM) for 72 h; an MTT assay was used to measure the effects of TSA on PC3 cell proliferation.	27571418 27548148 31289542

In vivo

Administration of Trichostatin A at 0.5 mg/kg for 4 weeks displays potent antitumor activity in the N-methyl-N-nitrosourea carcinogen-induced rat mammary carcinoma model, without any measurable toxicity at doses up to 5 mg/kg. ^[1] Single intraperitoneal doses of 10 mg/kg Trichostatin A in nontransgenic and spinal muscular atrophy (SMA) model mice results in increased levels of acetylated H3 and H4 histones and modest increases in survival motor neuron (SMN) gene expression. Administration of Trichostatin A at 10 mg/kg/day improves survival, attenuates weight loss, and enhances motor behavior in the SMA model mice. ^[5]

Protocol

Kinase Assay: ^[1]	- Collapse In vitro HDAC activity: Total cellular extracts are prepared from each breast cancer cell line (MCF-7, T-47D, ZR-75-1, BT-474, MDA-MB-231, MDA-MB-453, CAL 51, or SK-BR-3). A 20 μL crude cell extract (~2.5 ×10⁵ cells), in the presence of varying concentrations of Trichostatin A in 0.1% (v/v) ethanol or 0.1% (v/v) ethanol as vehicle control, are incubated for 60 minutes at 25 °C with 1 μL (~1.5 × 10⁶ cpm) of [³H]acetyl-labeled histone H4 peptide substrate (NH2-terminal residues 2-20) that has been acetylated with [³H]acetic acid, sodium salt (3.7 GBq/mmol) by an in vitro incorporation method. Each 200 μL reaction is quenched with 50 μL of 1 M HCl/0.16 M acetic acid and extracted with 600 μL of ethyl acetate, and released [³H]acetate is quantified by scintillation counting. IC50 values are determined graphically using nonlinear regression to fit inhibition data to the appropriate dose-response curve.
Cell Research: ^[1]	- Collapse Cell lines: MCF-7, T-47D, ZR-75-1, BT-474, MDA-MB-231, MDA-MB-453, CAL 51, and SK-BR-3 Concentrations: Dissolved in absolute ethanol, final concentrations ~10 μM Incubation Time: 96 hours Method: Cells are exposed to various concentrations of Trichostatin A for 96 hours. After treatment, cell proliferation is estimated using the sulforhodamine B colorimetric assay. Cell viability is determined by trypan blue exclusion. (Only for Reference)
Animal Research: ^[1]	- Collapse Animal Models: Inbred virgin female (Ludwig/Wistar/Olac) rats bearing tumors induced with NMU Dosages: ~5 mg/kg/day Administration: Injection s.c. (Only for Reference)

References

- Collapse

Solubility (25°C)

In vitro	DMSO	23 mg/mL (76.05 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 2% DMSO+30% PEG 300+2% Tween 80+ddH2O For best results, use promptly after mixing.	3mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Trichostatin A (TSA) SDF

Molecular Weight	302.4
Formula	C₁₇H₂₂N₂O₃
CAS No.	58880-19-6
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	N/A

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2020-05-15)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03901053	Recruiting	Device: Reaktiv AFO\|Device: PhatBrace AFO	Foot Injuries and Disorders	Jason Wilken\|Minneapolis Veterans Affairs Medical Center\|Walter Reed National Military Medical Center\|Henry M. Jackson Foundation for the Advancement of Military Medicine\|Center for Veterans Research and Education\|University of Delaware\|Johns Hopkins Bloomberg School of Public Health\|University of Iowa	February 27 2020	Not Applicable
NCT03887650	Recruiting	Drug: Liposomal Bupivicaine 1.3%\|Drug: Bupivacaine 0.5%	Post-operative Pain\|Total Shoulder Arthroplasty\|Osteoarthritis of the Shoulder\|Pain Management	Hartford Hospital	January 14 2019	Phase 4
NCT03838926	Recruiting	Drug: Trichostatin A	Relapsed or Refractory Hematologic Malignancies	Vanda Pharmaceuticals	September 27 2018	Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
I would like to obtain the enantiomers of TSA, as separate chemicals: R-TSA and S-TSA. Do you have any ideas?
Answer:
Our S1045 Trichostatin A (TSA) is R enantiomer.

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Selective HDAC Inhibitor

RGFP966 : HDAC3-selective, IC50=80 nM.
Selective HDAC Inhibitor

Rocilinostat (ACY-1215) : HDAC5-selective, IC50=5 nM.
Most Potent HDAC Inhibitor

Quisinostat (JNJ-26481585) : HDAC1, IC50=0.11 nM; HDAC2, IC50=0.33 nM.
FDA-approved HDAC Inhibitor

Vorinostat (SAHA, MK0683) : Approved by FDA against cutaneous T cell lymphoma.
Newest HDAC Inhibitor

RG2833 (RGFP109) ^New : Brain-penetrant HDAC inhibitor with IC50 of 60 nM and 50 nM for HDAC1 and HDAC3, respectively.

Related HDAC Products

LMK-235 ^New

LMK-235 is a selective inhibitor of HDAC4 and HDAC5 with IC50 of 11.9 nM and 4.2 nM, respectively.
CAY10603 ^New

CAY10603 is a potent and selective HDAC6 inhibitor with IC50 of 2 pM, >200-fold selectivity over other HDACs.
Domatinostat (4SC-202) ^New

4SC-202 is a selective class I HDAC inhibitor with IC50 of 1.20 μM, 1.12 μM, and 0.57 μM for HDAC1, HDAC2, and HDAC3, respectively. Also displays inhibitory activity against Lysine specific demethylase 1 (LSD1). Phase 1.
Panobinostat (LBH589)

Panobinostat (LBH589) is a novel broad-spectrum HDAC inhibitor with IC50 of 5 nM in a cell-free assay. Panobinostat (LBH589) induces autophagy and apoptosis. Panobinostat effectively disrupts HIV latency in vivo. Phase 3.
Vorinostat (SAHA)

Vorinostat (suberoylanilide hydroxamic acid, SAHA) is an HDAC inhibitor with IC50 of ~10 nM in a cell-free assay. Vorinostat abrogates productive HPV-18 DNA amplification.
Entinostat (MS-275)

Entinostat (MS-275) strongly inhibits HDAC1 and HDAC3 with IC50 of 0.51 μM and 1.7 μM in cell-free assays, compared with HDACs 4, 6, 8, and 10. Entinostat induces autophagy and apoptosis. Phase 3.
Romidepsin (FK228, Depsipeptide)

Romidepsin (FK228, depsipeptide) is a potent HDAC1 and HDAC2 inhibitor with IC50 of 36 nM and 47 nM in cell-free assays, respectively. Romidepsin (FK228/depsipeptide) controls growth and induces apoptosis in neuroblastoma tumor cells.

Features:More effective than other classical HDAC inhibitors such as TSA, TPX, and butyrate.
RGFP966

RGFP966 is an HDAC3 inhibitor with IC50 of 0.08 μM in cell-free assay, exhibits > 200-fold selectivity over other HDAC.
Tubastatin A

Tubastatin A is a potent and selective HDAC6 inhibitor with IC50 of 15 nM in a cell-free assay. It is selective against all the other isozymes (1000-fold) except HDAC8 (57-fold). Tubastatin A promotes autophagy and increases apoptosis.
Mocetinostat (MGCD0103)

Mocetinostat (MGCD0103) is a potent HDAC inhibitor with most potency for HDAC1 with IC50 of 0.15 μM in a cell-free assay, 2- to 10- fold selectivity against HDAC2, 3, and 11, and no activity to HDAC4, 5, 6, 7, and 8. Mocetinostat (MGCD0103) induces apoptosis and autophagy. Phase 2.

Choose Your Country or Region

By Signaling Pathways

By product type

Trichostatin A (TSA)